Non-alcoholic fatty liver disease resolution following sleeve gastrectomy

Algooneh, Ardeshir; Almazeedi, Sulaiman; Al-Sabah, Salman; Ahmed, Maha Abdul Aziz; Othman, Feras

doi:10.1007/s00464-015-4426-0

Cited by 34 publications

(20 citation statements)

References 26 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[115][116][117][118][119][120][121][122][123][124][125][126][127][128][129][130][131][132][133] A schematic representation of the search in the online databases and the identification, exclusion and selection of the articles is presented in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review

2017

View full text Add to dashboard Cite

CONTEXT AND OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) has been increasingly diagnosed worldwide and is now recognized as a source of public health concern. It comprises a wide spectrum of histological features that range from simple steatosis to severe forms of fibrosis, steatohepatitis and even cirrhosis. The impact of bariatric surgery on the course of NAFLD in individuals with obesity has been extensively studied. DESIGN AND SETTING: Narrative review; public university hospital. METHODS: A comprehensive review was conducted based on an online search on the electronic databases MEDLINE and LILACS using the MeSH terms "fatty liver" and "bariatric surgery". RESULTS:The exact mechanisms that lead to improvement in NAFLD following bariatric surgery are not completely understood. Since Roux-en-Y gastric bypass (RYGB) is the bariatric surgical procedure most performed worldwide, it is also the one from which the effects on NAFLD have been most studied, although there is also consistent evidence regarding the effects from gastric banding, sleeve gastrectomy and biliopancreatic diversions. CONCLUSION: According to the currently available evidence, bariatric surgery leads to significant improvement in NAFLD. Further research, especially by means of randomized controlled trials enrolling larger cohorts of individuals, is needed to determine the optimal procedure for this group of subjects. RESUMO CONTEXTO E OBJETIVO:A doença hepática gordurosa não alcoólica (DHGNA) tem sido diagnosticada com maior frequência em todo o mundo na atualidade, sendo agora reconhecida como motivo de preocupação em saúde pública. Abrange um amplo espectro de alterações histológicas que variam desde a simples esteatose até formas graves de fibrose, esteato-hepatite e até cirrose. O impacto da cirurgia bariátrica sobre o curso da DHGNA em indivíduos com obesidade tem sido profundamente estudado. TIPO DE ESTUDO E LOCAL: Revisão narrativa; hospital universitário público. MÉTODOS: Uma revisão abrangente da literatura foi conduzida baseada na pesquisa on-line nas bases de dados eletrônicas MEDLINE e LILACS por meio dos termos MeSH "fígado gorduroso" e "cirurgia bariátrica". RESULTADOS: Os mecanismos exatos que levam à melhora da DHGNA após a cirurgia bariátrica não são completamente conhecidos. Como o bypass gástrico em Y de Roux é a cirurgia bariátrica mais realizada em todo o mundo, é também o procedimento cujos efeitos sobre DHGNA foram mais estudados, embora haja também evidências consistentes sobre os efeitos de banda gástrica, gastrectomia vertical e derivações biliopancreáticas. CONCLUSÃO: De acordo com as evidências atualmente disponíveis, a cirurgia bariátrica leva à melhora significativa da DHGNA. Mais estudos, especialmente por meio de ensaios clínicos randomizados e controlados, recrutando coortes maiores de indivíduos, são necessários para determinar o melhor procedimento para esse grupo de pacientes.

show abstract

Section: Resultsmentioning

confidence: 99%

“…A retrospective study was conducted by Algooneh et al 129 on 84 patients diagnosed with NAFLD prior to undergoing SG.…”

Section: Sleeve Gastrectomymentioning

confidence: 99%

Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review

2017

View full text Add to dashboard Cite

show abstract

“…During the year of the patients' follow-up, a resolution of their metabolic symptoms was found in 92% of patients. 21,22 The inability of patients to attend their follow-up appointments was one of the difficulties of this study; monitoring and follow-up of patients for 1 year or more is hampered by insurers. In terms of pharmacoeconomics, this indicates that there is a decrease of up to 82% of the costs associated with the management and treatment of comorbidities secondary to obesity, in relation to the overall cost of the surgery; this is small with regards to the social impact this brings to the patient.…”

Section: Discussionmentioning

confidence: 98%

“…Currently, the use of ultrasonography has facilitated the early diagnosis of this pathology, but it is clear that a decrease of 50% EWL leads to the resolution of this pathology. 21 In a meta-analysis, Buchwald showed that remission of hypertension is not dependent on the type of procedure, but rather that the number of antihypertensive drugs a patient was taking before or around the time of the surgery defines a patient's total or partial remission. [22][23][24] A Swedish study showed more benefits with the bypass, although it is worth mentioning that this study did not include the gastric sleeve.…”

Section: Discussionmentioning

confidence: 99%

Obesity-related Metabolic Comorbidities Remission in Postbariatric Surgery Patients

Dorado¹,

López²,

Martin³

2017

WJOLS

View full text Add to dashboard Cite

show abstract

“…62 Melania Manco et al, found 100% improvement of NASH in adolescents, one year after SG and in their study, SG was most effective than lifestyle change and intragastric weight loss device. 41 Another study resulted in improvement of liver steatosis (66.6%), fibrosis (68%) and NAFLD activity score, 3 months after SG.…”

Section: Researchmentioning

confidence: 99%

Role of bariatric surgery in treatment of non-alcoholic fatty liver disease

Kermansaravi

Ebrahimian

Delbari

et al. 2017

J. contemp. med. sci.

View full text Add to dashboard Cite

The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is increasing due to increasing of morbid obesity prevalence worldwide. It has been demonstrated that weight loss is the corner stone of NAFLD/NASH treatment. Various options are available for weight loss in obese patients, such as life style modification, pharmacotherapy, endoscopic interventions and bariatric/metabolic surgery. Performing bariatric/meta bolic surgery only for NAFLD/NASH treatment is on debate, but it has been proven that bar iatric surgery is the most durable and effective treatment for weight loss and obesity-related comorbidities.

show abstract

Non-alcoholic fatty liver disease resolution following sleeve gastrectomy

Abstract: Weight loss after LSG effectively resolved NAFLD in more than half of the obese patients in this study and can prove to be a useful tool in tackling the disease in the future.

Cited by 34 publications

References 26 publications

Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review

Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review

Obesity-related Metabolic Comorbidities Remission in Postbariatric Surgery Patients

Role of bariatric surgery in treatment of non-alcoholic fatty liver disease

Contact Info

Product

Resources

About